Tumors in Medical Technology

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announced today the initiation of a Phase 1 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric patients. This Phase 1 study is now ope...

New Proton Therapy Equipment Enables More Tumors to be Treated

JACKSONVILLE, Fla. Feb. 23 /PRNewswire/ -- An advance in the way protons are delivered at the University of Florida Proton Therapy Institute enables physicians to treat tumors that are deeper in the body, tumors that are very large and tumors that are situated closer to vital organs. Calle...

Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer

EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against hum...

Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain

Study Demonstrates Differentiation of Primary Tumors From Metastases in the Brain With Accuracy Near 90% Identifying Whether a Brain Malignancy is a Primary Tumor or a Metastasis is a Recurring Challenge for Pathologists Using Current Technologies Accurately Differentiating...

Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma

SAN DIEGO, April 14 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2008 AACR Annual Meeting that its integrin-targeted PI3 kinase inhibitor, SF1126, was shown to cause significant tumor regression in combination with rapamycin in a...

St. Jude Study Offers New Hope for Children With Kidney Tumors Deemed Inoperable

Surgeons were able to save part of each kidney in patients with bilateral Wilms tumor, regardless of how the tumors appear on preoperative scans MEMPHIS, Tenn., March 24 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital physicians have demonstrated that children with bilater...

Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More

Interventional Radiologists' Outpatient Procedure Uses Heat to Destroy Lung Tumors WASHINGTON, March 17 /PRNewswire-USNewswire/ -- Radiofrequency ablation (RFA) -- an interventional treatment that "cooks" and kills lung cancer tumors with heat -- greatly improves survival time from primary...

Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma

WESTMINSTER, Colo., Nov. 12 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH ) today announced the initiation of patient enrollment in a Phase 1, non-randomized, open-label, multi-center dose escalation study of the Company's targeted chemotherapeutic agent RH1 in patients wit...

Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference

- favorable pharmacokinetic and safety data observed in first clinical trial of novel Fleximer(TM) anticancer agent - CAMBRIDGE, Mass., Oct. 24 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced interim results of a Phase I study of its lead product candidate, XMT-1...

Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)

NUTLEY, N.J., Oct. 23 /PRNewswire/ -- Today, Roche announced positive results from a Phase I trial of R1507, a human monoclonal antibody to target IGF-1R (insulin-like growth factor receptor), in patients with solid tumors. IGF-1 is one of the most potent natural activators of the AKT and MAPK...

Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Th...

Peregrine Researchers Report Data Showing Bavituximab's Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half - - Data Further Confirm Bavituximab's Potential to Enhance Multiple Combination Regimens for Cancer Therapy - ATLANTA, and TUSTIN, C...

Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors

RALEIGH, N.C., Aug. 5 /PRNewswire/ -- Cancer Centers of North Carolina , an affiliate of US Oncology, Inc. , continues to offer cutting-edge treatment options to its patients through the addition of High Dose Rate (HDR) brachytherapy. This latest advance in brachytherapy a...

AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors

Early-stage renal masses should be treated with nephron-sparing approaches when possible LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Radical nephrectomy (complete removal of the affected kidney) is not the best treatment for most small kidney tumors because it puts patients at risk fo...

Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors

More Than 75 Percent of Patients Diagnosed Have Small Renal Cell Tumors; Safe Interventional Radiology Treatment Shown Near 100 Percent Effective in Destroying Localized Tumors, Says Johns Hopkins Study SAN DIEGO, March 9 /PRNewswire-USNewswire/ -- Freezing kidney tumors -- using a safe mi...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

- Data show significant 66% reduction in risk of disease progression versus placebo - Sandostatin LAR more than doubled time without tumor growth for a median of 14 months compared to six months on placebo - Results support Sandostatin LAR as first treatment after surgery in certain pati...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

Schering-Plough Receives CHMP Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL Sachet Presentation -- Providing Potential New Treatment Options for EU Patients with Certain Primary Brain Tumors KENILWORTH, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Schering-Plough Corp...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot - 77% of patients with pancreatic NET experienced clinical benefit when treated with ...

FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors

Pathwork Diagnostics' Gene Expression Test Is the First to Receive FDA Clearance for Diagnosis of Uncertain Tumors; Problem Affects 200,000 New U.S. Cancer Cases Annually SUNNYVALE, Calif., July 31 /PRNewswire/ -- Pathwork Diagnostics, Inc., a molecular diagnostics com...

Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors

INDIANAPOLIS, June 4 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today reported interim data from a Phase I study of its lead product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluate...

Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors

- Primary study objectives include evaluation of safety and tolerability, as well as selection of a recommended dose for Phase 2 trials - ROCKVILLE, Md., May 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that it has initiated dosing in a Phase 1 cl...

St. Jude Finds Young Age May Give Survival Advantage to Children With Certain Brain Tumors

The improved survival of children under 3 years old with diffuse pontine glioma compared to older children suggests that the biological properties of this cancer may be distinct in young patients MEMPHIS, Tenn., May 29 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital investiga...

Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 2 clinical trial of carfilzomib (PR-171), a selective blocker of proteasome activity, in relapsed solid tumors. A Phase 1b dose-escalation trial of carfilzomib in pat...

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

BETHESDA, Md., April 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced the start of a phase 1 clinical trial with its BiTE(R) antibody M...

Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors

BONITA SPRINGS, Fla., Jan. 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug (AFP-464) for the treatment of cancer. The first patient was dosed in December 20...

Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product c...

Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors

Phase 1b/2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in Patients with Relapsed Solid Tumors SOUTH SAN FRANCISCO, Calif., and SAN ANTONIO, Oct. 10 /PRNewswire/ -- Proteolix, Inc. and South Texas Accelerated Research Therapeutics (START) today announced the enro...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

NEW HAVEN, Conn., Sept. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that an investigator-sponsored trial of its lead anti-cancer agent Cloretazine(R) (VNP40101M) in combination with Temodar(R) (temozolomide) in relapsed or progressive adult malignan...

Peregrine Reports Data Showing Bavituximab's Potential to Shrink Prostate Tumors

- Adding Bavituximab to Standard Regimen of Androgen Deprivation and Chemotherapy Reduced Size of Formerly Resistant Tumors by More than Half - - Data Further Confirm Bavituximab's Potential to Enhance Multiple Combination Regimens for Cancer Therapy - ATLANTA, and TUSTIN, C...

Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice

PHILADELPHIA, March 15, 2007-- The cause of one notorious childhood disease, poliovirus, could be used to treat the ongoing threat of another childhood disease, neuroblastoma. In the March 15 issue of Cancer Research, researchers from Stony Brook University report that an attenuated -- or non-viru...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by Combining Cytokines With Peregrine's Anti-PS Antibodies Demonstrate Increased Anti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical s...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Phase III trial planned Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of a Phase I/IIa study presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago demonstrate the clinical activity of cilengitide in patients with newly dia...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

HDAC Inhibitor MGCD0103 Demonstrates substantial Response Rate in Two Clinical Trials Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine Exelixis Reports Comprehensive XL880 Phase I Data At ASCO Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 a...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...n the trial. Importantly, in patients with tumors harboring activating KRAS mutations, PFS was sig...ype KRAS tumors, but patients with KRAS mutant tumors were negatively affected when Vectibix was added t...lieve Vectibix should not be used in patients with tumors containing activating KRAS mutations." ...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Erbitux/Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13," and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these m...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...tases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or mult...ul benefit for advanced cancer patients with solid tumors that have metastasized to the bone, and to patient... next year." Bone metastases, the spread of tumors to the bone, are a serious concern for many advanc...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...m drug that has shown to be active in many solid tumors in human clinical studies. Access has commenced a...num drug that has shown to be active in many solid tumors in human clinical studies. Platinum drugs are one ...been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Ac...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...ls in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than wi...